Gilead Sciences appoints Véronique Walsh as General Manager of UK and Ireland operations

Véronique Walsh

Gilead Sciences has announced the appointment of Véronique Walsh as General Manager of its UK and Ireland operations, managing a portfolio of products spanning HIV, Hepatitis, Oncology and COVID-19.

Véronique joins Gilead from Bristol Myers-Squibb (BMS), where she and the past two years as General Manager for Benelux, building on a 25-year career in the pharmaceutical industry.

During her time at BMS, Walsh also worked as the interim General Manager for the UK & Ireland, delivering double-digit growth and helping navigate the company through a time of uncertainty in the period preceding Brexit.

As well as leadership roles in innovative medicines and virology at BMS, Walsh has held commercial roles at Sanofi Pasteur MSD and Aventis Pasteur MSD in the UK and France.

She began her career as a General Practitioner with a speciality in toxicology and is passionate about bringing science and innovation to patients.

Commenting on her appointment, Véronique said: “I am delighted to join Gilead. The company has secured significant advances in therapy areas such Hepatitis C and HIV and is making exciting developments in Haematology and Oncology. Furthermore, Gilead continues to grow its talent and its well-deserved reputation for innovation in areas of high unmet needs.

“My goal has always been to ensure patients have access to the best possible care. Gilead stands out within our industry as a company wholeheartedly committed to that goal. Building on Gilead’s legacy of collaboration with patient groups, healthcare professionals, and the public and private sectors, we will work to create a better healthcare environment, and ultimately better outcomes, for patients in the UK and Ireland.”